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QUALITY OF LIFE SCALE IN PARKINSON’S DISEASE
PDQ-39 - (Brazilian Portuguese version) to assess patients  
with and without levodopa motor fluctuation
Renata Guzzo Souza1, Vanderci Borges2,  
Sonia Maria Cesar de Azevedo Silva2, Henrique Ballalai Ferraz2
ABstrAct - Quality of life (QoL) is an important treatment outcome indicator in Parkinson’s disease (PD). 
the aim of this study is to assess the usefulness of the Parkinson’s disease questionnaire - PDQ-39 (Brazil-
ian Portuguese Version) in measuring QoL of PD patients with or without motor fluctuations. Fifty-six PD 
patients with mean disease duration of 7.4 years were assessed and 41 of them (73.3%) had motor fluctu-
ations. the PDQ-39 has eight dimensions ranging from 0 to 100; being the higher the score, the worse the 
QoL. comparing groups with and without motor fluctuations showed that the dimensions mobility, activ-
ities of daily living (ADL), communication and bodily discomfort scored higher in the fluctuating group. 
there was a tendency to see that the higher the Hoehn and Yahr (HY) scale stages, the higher the PDQ-
39 scores. Patients suffering from the disease for more than five years had worse PDQ-39 scores only in 
the items ADL and communication, when compared with those with the disease for ≤ 5 years. the PDQ-39 
is an instrument that detects decrease in QoL of PD patients and the presence of motor fluctuations pre-
dicts QoL reduction.
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Escala para qualidade de vida na doença de Parkinson – PDQ 39 (versão do Português falado no 
Brasil) como instrumento para avaliação de pacientes com e sem flutuação motora decorren-
te da levodopa
resumo - A qualidade de vida (QdV) é um item importante para se mensurar o sucesso do tratamento na 
doença de Parkinson (DP). o objetivo deste estudo foi o de avaliar a utilidade do questionário sobre a do-
ença de Parkinson - PDQ-39 (versão em língua portuguesa falada no Brasil) para mensurar a QdV dos pa-
cientes parkinsonianos com e sem flutuação motora. Nós avaliamos 56 pacientes com DP com tempo médio 
da doença de 7,4 anos, e destes 41 (73,3%) apresentavam flutuação motora. A PDQ-39 tem oito domínios 
que variam de 0 a 100 e quanto maior o escore pior a QdV. A comparação dos grupos de pacientes com e 
sem flutuação motora mostrou que os domínios: mobilidade, atividades de vida diária, comunicação e des-
conforto corporal tinham escores maiores nos flutuadores. Quanto maiores os estágios de Hoehn e Yahr 
(HY) da doença, maiores os escores da PDQ-39. Pacientes com mais de 5 anos de evolução da doença mos-
traram escores piores da PDQ39 apenas nos itens atividades da vida diária e comunicação se comparados a 
pacientes com 5 anos ou menos de doença. A PDQ-39 é um instrumento capaz de detectar declínio da QdV 
de pacientes com DP e a presença de flutuação motora é um preditor para redução na QdV. 
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Parkinson’s disease (PD) ranks second in prev-
alence of degenerative disease of the nervous sys-
tem, after Alzheimer’s disease, and it is estimated 
that 0.3% of population is affected1. A recent Bra-
zilian study carried out in the town of Bambuí, state 
of minas Gerais, Brazil, showed that PD affects 3.3% 
of individuals aged over 65 years2.
especially in its initial stages, PD symptoms are 
mainly motor, later on cognitive dysfunctions and 
mood disorders appear. Although levodopa still is 
the cornerstone of PD treatment, its prolonged use 
is associated to motor and non-motor complications. 
Non-motor complications include nausea, vomiting, 
orthostatic hypotension, sleepiness, hallucinations 
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and delusions. the main motor complications are ef-
fect fluctuations and dyskinesias. Fluctuations may 
either be predictable, as the wearing-off of medica-
tion, or unpredictable, as random oscillations (on-off 
effect) or delayed “on” effect. Dyskenesias are char-
acterized by involuntary movements, sometimes ste-
reotyped. they may emerge either during the motor 
benefit period (“on” period dyskenesia) or during 
the absence of this motor effect (“off” period dys-
kenesia). Although daily activities may be affected 
since the beginning, progression of symptoms and 
complications cause a progressive decrease in the 
QoL. In this context, QoL refers to the impact of the 
disease on patients themselves, including physical, 
emotional, and socio-economic aspects3. 
there are several instruments to measure health 
and health-related quality of life that require check-
ing reliability, accessibility, and receptivity, as well as 
interpretation, in order to be validated. there are 
several PD-specific instruments to assess motor func-
tions, such as the unified Parkinson’s Disease rat-
ing scale (uPDrs), the schwab-england scale, and 
others4,5. However, these scales do not take into ac-
count the actual impact of the disease on patients’ 
daily life, because they do not have a satisfactory ap-
proach of cognitive and emotional symptoms. there 
are several instruments to assess quality of life in PD: 
PIms (Parkinson’s Disease Impact scale), PLQ (Parkin-
son Lebensqualität - Parkinson’s Disease Quality of 
Life Questionnaire), PDQL (Parkinson’s Disease Qual-
ity of Life Questionnaire), PDQ-39 (Parkinson’s Dis-
ease Questionnaire), and sF-36 (Health status Ques-
tionnaire, short form), among others6-10. the 39-item 
Parkinson’s disease questionnaire (PDQ-39) is one of 
the most often used instruments to measure treat-
ment effect on QoL. It assesses several clinical fea-
tures and has been tested and used in several stud-
ies and is available in several languages. It was devel-
oped interviewing PD patients about harmful effects 
of the disease regarding several aspects of their dai-
ly life. At first, 65 items were used in a pilot test. re-
dundant items were eliminated, thus originating a 
smaller questionnaire with 39 questions divided into 
8 dimensions and measuring the impact of PD on the 
QoL in the previous month9. recentely, a Brasilian 
version of it was valited11.
the aim of this study is to assess the usefulness of 
a Brasilian version of PDQ-39 in PD patients with and 
without motor fluctuation. 
METhOD
Patients – using the uK Parkinson’s Disease society’s 
Brain Bank12 criteria, we evaluated 56 patients with the di-
agnosis of Parkinson’s disease undergoing outpatient treat-
ment at the movement Disorders unit of the Department 
of clinical Neurology of the universidade Federal de são 
Paulo (uNIFesP). 
men and woman patients aged over 40 years, in any 
phase of the disease, who accepted to participate in the 
study and signed the informed consent form were includ-
ed. Patients with severe cognitive impairment, evaluated by 
neurologists using mini-mental state examination (mmse), 
who were not able to answer the questionnaire were ex-
cluded.
Procedure – First, a non-healthcare professional trans-
lated the original english version of the PDQ-39 into Brazil-
ian Portuguese. the back-translation was done by another 
translator to check possible mistakes or cultural biases. the 
questionnaire was then reviewed by its authors to make it 
easily accessible and compatible with the patient’s reality.
the PDQ-39 comprises 39 questions with five different 
options of answer related to the frequency of the disease 
manifestation. the answers refer to impact of the illness on 
the patient’s life in the previous month, as explained be-
fore the interview. the 39 questions are divided into 8 di-
mensions: mobility (10 questions), activities of daily living 
(ADL) (6), emotional well-being (6), stigma (4), social sup-
port (3), cognition (4), communication (3), and bodily dis-
comfort (3). 
the score for each question ranges from zero (0) to four 
(4): “never”=0; “occasionally”=1; “sometimes”=2; “often”= 
3; “always”=4. the final score is the result of the following 
equation: the sum of each question score divided by the 
result times 4 (the maximal score for each question), divid-
ed by the total number of questions. this result is multi-
plied times by 100. each dimension score ranges from 0 to 
100 in a linear scale, in which zero is the best and 100 the 
worst quality of life13.
After the patient’s consent, the questionnaire, clinical 
and epidemiologic assessment forms were applied during 
routine outpatient visits. Patients were encouraged to an-
swer the questionnaire by themselves. one of the authors 
(rGs) interviewed those who could not answer alone due 
to several reasons, such as decreased visual acuity, signifi-
cant tremor, and akinesia. 
the Hoehn and Yahr (HY) scale, ranging between stag-
es 1 to 5, was used to assess disease severity and allow fu-
ture comparison of results14. Data was collect from August 
2005 until November 2006.
the patients were divided into two groups: those with 
fluctuations and/or dyskenesias and those without these 
changes. the criteria used to divide them into these groups 
were defined based on the interview and confirmed by the 
attending neurologist. 
Statistical analysis – the spearman correlation test was 
used to verify the relation between disease duration, HY 
stage, and presence of fluctuations, as well as to check if the 
dimensions were statistically significant. the mann-whitney 
test was used to detect possible differences in each dimen-
sion of PDQ-39 in groups of patients with presence or ab-
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sence of fluctuations and in groups with five or less years of 
disease duration and more than five years of duration. 
RESULTS
Fifty-six PD patients were seen at the outpatient 
clinics of the movement Disorders unit, at the uni-
versidade Federal de são Paulo (uNIFesP): 32 (57.2%) 
were male and 24 (42.8%), female. the mean age 
was 62.7 years, age range of 40 to 81 years; and the 
mean PD duration was 7.4 years. Forty-one (73.3%) 
patients had motor fluctuations and 15 (26.7%) sta-
bilized with the use of medication.
the patient distribution in the HY scale was: 
in stage 1, five patients (8.9%); stage 1.5, four pa-
tients (7.1%); stage 2, nine patients (16%); stage 2.5, 
twenty patients (35.7%); stage 3, eighteen patients 
(32.1%). No stage-4 and 5 patients were assessed. 
out of 56 patients, 49 (87.5%) were on levodopa. 
Patients without fluctuations used a mean levodopa 
dose of 216 mg/day (ranging from 250 mg to 500 mg/
day) while patients with motor complication took a 
mean dose of 537 mg (ranging from 250 mg to 2500 
mg). seventeen patients (29.8%) used anti-depres-
sive medication. 
the 56 patients had the following mean scores 
and respective standard deviations in the eight di-
mensions: mobility 50.9±26.1; ADL 44.4±28.5; emo-
tional well-being 48.1±25.5; stigma 33.5±31.8; so-
cial support 67.7±12.7; cognition 32.5±19.8; commu-
nication 30.8±28.2 and bodily discomfort 43.5±25.9. 
cronbach’s alpha coefficient of the 39 questions in-
cluded in the PDQ-39 was 0.923, demonstrating in-
ternal consistency and high reliability (p<0.001). 
table 1 depicts the mean scores of the eight PDQ-39 
dimensions in each HY stage. As expected, the spear-
man test showed a correlation between HY stages 
and the degree of severity of the PDQ-39 dimensions, 
except for the items cognitions and social support.
As seen in Figure, the eight dimensions assessed 
showed the following mean scores: in the dimension 
mobility, it is 30.5 for patients without fluctuations 
and 58.3 for those with fluctuations; in ADL, 25.7 
for patients without fluctuations and 51.3 with fluc-
tuations; emotional well-being, 38.6 in those with-
out fluctuations and 51.6 with fluctuations; in stig-
ma, 22.9 in patients without fluctuations and 37.3 
with fluctuations; in social support, 69.4 for patients 
without fluctuations and 67.1 with fluctuations; in 
cognition, 26.7 for patients without fluctuations and 
34.6 with fluctuations; in communication, 10.0 for 
patients without fluctuations and 38.4 with fluctu-
ations; in bodily discomfort, 32.2 in patients with-
out fluctuations and 47.6 with fluctuations. Accord-
ing to the mann-whitney test, the differences were 
statistically significant (p<0.05) for the items mobili-
ty, ADL, emotional well-being, communication, and 
bodily discomfort. 
table 2 depicts that disease duration only corre-
lates with disease severity in the following PDQ-39 
dimensions: ADL and communication. 
Table 1. Mean scores of PDQ39 dimensions at Hohen and Yahr stages (n=56).
stage 1
mean score 
(sD)
stage 1.5
mean score 
(sD)
stage 2
mean score 
(sD)
stage 2.5
mean score 
(sD)
stage 3
mean score 
(sD)
correlation 
coefficient 
(p)
mobility 29.0
(15.3)
24.0
(8.3)
43.0
(25.3)
44.0
(26.1)
72.0
(17.2)
0.60
(p<0.001)
Activities of daily living 13.0
(7.2)
9.0
(8.6)
52.0
(22.4)
39.0
(27.1)
61.0
(26.6)
0.50
(p<0.001)
emotions 43.0
(29.8)
32.0
(11.0)
46.0
(24.3)
42.0
(25.8)
58.0
(26.6)
0.26
(p<0.05)
stigma 10.0
(16.3)
11.0
(21.9)
40.0
(38.0)
30.0
(31.0)
44.0
(30.2)
0.31
(p<0.05)
social support 70.0
(13.9)
69.0
(4.2)
67.0
(8.3)
62.0
(20.2)
71.0
(13.8)
0.09
(Ns)
cognitions 18.0
(24.4)
28.0
(24.2)
35.0
(18.5)
32.0
(21.8)
35.0
(16.9)
0.19
(Ns)
communication 3.0
(7.5)
6.0
(12.5)
32.0
(35.0)
35.0
(26.7)
37.0
(27.4)
0.36
(p<0.01)
Bodily discomfort 27.0
(10.9)
23.0
(18.5)
38.0
(20.5)
42.0
(31.2)
55.0
(20.9)
0.41
(p< 0.01)
statistical test, spearman correlation analysis; Ns, not significant.
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DISCUSSION
It is well known that PD is a chronic disease that 
significantly affects quality of life15. the PDQ-39 is fre-
quently used to measure the impact of the disease on 
QoL, because it is the questionnaire most used world-
wide and it includes the a number of items assessing 
PD impact. other instruments, such as the short Form 
36 Health survey (sF 36), Nottingham Health Profile, 
sickness Impact Profile (sIP), among others, are good 
but general scales, not PD-specific16. 
In the sample of 56 patients, 41 (73.3%) had motor 
fluctuations. these changes are related to disease pro-
gression and prolonged use of levodopa, and play an 
important role in reducing QoL, because they affect 
mainly mobility and daily life activities, and are asso-
ciated with muscle pain and depressive symptoms17,18. 
the absence of HY stage-4 and 5 patients in this 
sample is explained by the high cognitive impair-
ment, usually seen on these stages which made them 
unable to answer the questionnaire, thus being ex-
cluded from the study. 
this study showed that disease severity, when as-
sessed by Hohen and Yahr stages, harmfully affects 
QoL in activities involving motor skills19, as seen in 
table 1. the higher the disease stage, the worse the 
quality of life in aspects concerning physical inde-
pendence20,21.
studying the dimensions of emotional and cog-
nitive aspects, it was observed that the results were 
not as expected. that is, the lower the disease stage, 
the higher the impact on QoL. this may be explained 
by the patients’ initial reaction acknowledging they 
have an incurable, progressive disease and may be-
come physically, emotionally and economically de-
pendent, thus causing emotional problems. It is 
known that PD-associated depression sometimes 
precedes motor disabilities19,22. 
regarding the dimensions social support and 
stigma related to HY stages, previous studies have 
already shown that they are almost constant during 
the disease progression23, probably due to increased 
dissemination of information about PD by support 
groups or volunteer organizations clarifying it to the 
general population.
the presence of motor fluctuations causes a fast-
er decline in QoL when compared to those without 
fluctuation17, as depicted in Figure, where the di-
mensions requiring greater bodily and motor inde-
Figure. Mean scores of PDQ-39 dimensions 
in patients with and without motor fluctu-
ation. Mann-Whitney test showed statis-
tically significant differences (p<0.05) for 
mobility, activities of daily living (ADL), 
emotions, communication, and bodily dis-
comfort.
Table 2. Disease duration vs. mean scores of dimensions 
≤ 5 years  
(N=25)
mean scores 
(sD)
>5 years 
(N=31)
mean scores 
(sD)
mobility 47.5 (28.5) 53.6 (24.0)
Activities of daily living 32.8 (28.2) 53.8 (26.0)
emotional well-being 50.5 (26.3) 46.2 (24.9)
stigma 25.2 (27.6) 40.1 (33.5)
social support 68.0 (13.1) 67.5 (13.0)
cognition 30.7 (20.3) 33.9 (19.6)
communication 21.3 (27.4) 38.4 (26.8)
Bodily discomfort 40.7 (23.6) 45.7 (26.9)
mann-whitney test demonstrated significant differences (p<0.05) for 
activities of daily living and communication.
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pendence have higher scores in patients with fluctua-
tions, showing that motor deficits is an important 
factor in worsening QoL. Another factor that nega-
tively affects QoL in PD is disease duration, as de-
picted in table 2. However, this only happened in the 
items activities of daily life and communication. It is 
known that the longer the disease lasts, the worse 
the performance in all motor or cognitive activities, 
but in this sample we could not demonstrate statisti-
cally significant differences in most of dimensions. 
In conclusion, our data demonstrate that the PDQ-
39 is a multidimensional instrument approaching 
physical, emotional, and environmental factors that 
are useful in the medical practice. It is easily under-
stood and handled by patients, thus allowing a bet-
ter assessment of the disease progression and drug 
therapy. therefore, it is an important tool in making 
therapeutic decisions to minimize the effects of PD 
and improve the quality of life of PD patients.
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